The effects of protamine sulfate on clot formation time and clot strength thromboelastography variables for canine blood samples

American Journal of Veterinary Research

Volumn 75, Issue 4, 2014, Pages 338-343

  Bailey, Christopher J ^a   Koenigshof, Amy M ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHLORIDE; CITRATE SODIUM; HEPARIN; KAOLIN; PROTAMINE SULFATE;

ARTICLE; BLOOD CLOTTING TIME; CLOT STRENGTH; CONTROLLED STUDY; DOG; FEMALE; FRIEDMAN TEST; HEMATOCRIT; HYPOCOAGULABILITY; JUGULAR VEIN; MALE; MAXIMUM AMPLITUDE; MICROSCOPY; NONHUMAN; RATE OF CLOT FORMATION; REACTION TIME; REFRACTOMETER; THROMBOCYTE COUNT; THROMBOELASTOGRAPHY;

ANIMALS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DOGS; HEPARIN ANTAGONISTS; KAOLIN; MALE; PROTAMINES; THROMBELASTOGRAPHY;

EID: 84897051819     PISSN: 00029645     EISSN: 19435681     Source Type: Journal    
DOI: 10.2460/ajvr.75.4.338     Document Type: Article

References (39)

1. Sniecinski RM, Chandler WL. Activation of the hemostatic system during cardiopulmonary bypass. Anesth Analg 2011;113:1319-1333.
2. Reges RV, Vicente WV, Rodrigues AJ, et al. Retrograde autologous priming in cardiopulmonary bypass in adult patients: effects on blood transfusion and hemodilution. Rev Bras Cir Cardiovasc 2011;26:609-616.
3. Hirsh J, Raschke R, Warkentin TE, et al. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108:258S-275S.
4. Cormack JE, Forest RJ, Groom RC, et al. Size makes a difference: use of a low-prime cardiopulmonary bypass circuit and autologous priming in small adults. Perfusion 2000;15:129-135.
5. Jaques LB. A study of the toxicity of the protamine, salmine. Br J Pharmacol Chemother 1949;4:135-144.
6. Kresowik TF, Wakefield TW, Fessler RD II, et al. Anticoagulant effects of protamine sulfate in a canine model. J Surg Res 1988;45:8-14.
7. Lindblad B, Wakefield TW, Whitehouse WM Jr, et al. The effect of protamine sulfate on platelet function. Scand J Thorac Cardiovasc Surg 1988;22:55-59.
8. Adkins JR, Hardy JD. Sodium heparin neutralization and the anticoagulant effects of protamine sulfate. Arch Surg 1967;94:175-177.
9. Nielsen VG. Protamine enhances fibrinolysis by decreasing clot strength: role of tissue factor-initiated thrombin generation. Ann Thorac Surg 2006;81:1720-1727.
10. DeLaria GA, Tyner JJ, Hayes CL, et al. Heparin-protamine mismatch. A controllable factor in bleeding after open heart surgery. Arch Surg 1994;129:944-951.
11. Jobes DR, Aitken GL, Shaffer GW. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg 1995;110:36-45.
12. McLaughlin KE, Dunning J. In patients post cardiac surgery do high doses of protamine cause increased bleeding? Interact Cardiovasc Thorac Surg 2003;2:424-426.
13. Holloway DS, Summaria L, Sandesara J, et al. Decreased platelet number and function and increased fibrinolysis contributeto postoperative bleeding in cardiopulmonary bypass patients. Thromb Haemost 1988;59:62-67.
14. Wakefield TW, Whitehouse WM Jr, Stanley JC. Depressed cardiovascular function and altered platelet kinetics following protamine sulfate reversal of heparin activity. J Vasc Surg 1984;1:346-355.
15. Horrow JC. Thrombocytopenia accompanying a reaction to protamine sulfate. Can Anaesth Soc J 1985;32:49-52.
16. Kortchinsky T, Vigué B, Samama CM. Antagonisation des héparines et des nouveaux anticoagulants. Ann Fr Anesth Reanim 2013;32:37-49.
17. Butterworth J, Lin YA, Prielipp RC, et al. Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass. Ann Thorac Surg 2002;74:1589-1595.
18. Morgan M, Monnet E, Gaynor J. The effect of differing rates and injection sites on the amount of protamine delivered before detection of hemodynamic alterations in dogs. Vet Surg 2000;29:442-448.
19. Uechi M, Mizukoshi T, Mizuno T, et al. Mitral valve repair under cardiopulmonary bypass in small-breed dogs: 48 cases (2006-2009). J Am Vet Med Assoc 2012;240:1194-1201.
20. Ni Ainle F, Preston RJ, Jenkins PV, et al. Protamine sulfate downregulates thrombin generation by inhibiting factor V activation. Blood 2009;114:1658-1665.
21. Butterworth J, Lin YA, Prielipp R, et al. The pharmacokinetics and cardiovascular effects of a single intravenous dose of protamine in normal volunteers. Anesth Analg 2002;94:514-522.
22. Wiinberg B, Kristensen AT. Thromboelastography in veterinary medicine. Semin Thromb Hemost 2010;36:747-756.
23. Donahue S. OC. Thromboelastography: a tool for measuring hypercoagulability, hypocoagulability, and fibrinolysis. J Vet Emerg Crit Care 2005;15:9-16.
24. Vilar P, Couto CG, Westendorf N, et al. Thromboelastographic tracings in retired racing Greyhounds and in non-Greyhound dogs. J Vet Intern Med 2008;22:374-379.
25. Yamakage M, Tsujiguchi N, Kohro S, et al. The usefulness of celite-activated thromboelastography for evaluation of fibrinolysis. Can J Anaesth 1998;45:993-996.
26. Otto CM, Rieser TM, Brooks MB, et al. Evidence of hypercoagulability in dogs with parvoviral enteritis. J Am Vet Med Assoc 2000;217:1500-1504.
27. Spiess BD, Tuman KJ, McCarthy RJ, et al. Thromboelastography as an indicator of post-cardiopulmonary bypass coagulopathies. J Clin Monit 1987;3:25-30.
28. McNicol PL, Liu G, Harley ID, et al. Patterns of coagulopathy during liver transplantation: experience with the first 75 cases using thrombelastography. Anaesth Intensive Care 1994;22:659-665.
29. Shore-Lesserson L, Manspeizer HE, DePerio M, et al. Thromboelastography- guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999;88:312-319.
30. Flint SK, Wood RD, Abrams-Ogg AC, et al. Comparison of citrated native and kaolin-activated samples for thrombelastographic analysis in healthy dogs. Vet Clin Pathol 2012;41:249-255.
31. Bauer N, Eralp O, Moritz A. Establishment of reference intervals for kaolin-activated thromboelastography in dogs including an assessment of the effects of sex and anticoagulant use. J Vet Diagn Invest 2009;21:641-648.
32. Brooks MB, Randolph J, Warner K, et al. Evaluation of platelet function screening tests to detect platelet procoagulant deficiency in dogs with Scott syndrome. Vet Clin Pathol 2009;38:306-315.
33. Stockham SL, Scott MA. Fundamentals of veterinary clinical pathology. 2nd ed. Ames, Iowa: Blackwell Publishing Ltd, 2008.
34. Mochizuki T, Olson PJ, Szlam F, et al. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg 1998;87:781-785.
35. Nesheim ME, Taswell JB, Mann KG. The contribution of bovine factor V and factor Va to the activity of prothrombinase. J Biol Chem 1979;254:10952-10962.
36. Mast AE, Broze GJ Jr. Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase. Blood 1996;87:1845-1850.
37. Bolliger D, Szlam F, Azran M, et al. The anticoagulant effect of protamine sulfate is attenuated in the presence of platelets or elevated factor VIII concentrations. Anesth Analg 2010;111:601-608.
38. Bull B, Huse W, Brauer F, et al. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 1975;69:685-689.
39. LaDuca FM, Zucker ML, Walker CE. Assessing heparin neutralization following cardiac surgery: Sensitivity of thrombin time-based assays versus protamine titration methods. Perfusion 1999;14:181-187.